Sign In
Buy BIIB
$196.45
+0.490 (+0.250%)
At Close: Jun 04, 2026
3 Reasons to Buy Biogen Stock (and 1 to Sell)
10:15am, Friday, 12'th May 2023
Biogen has been struggling in recent years, but a couple of new products could help bolster its top line. The stock trades at a discount, which may be an opportunity, especially given the potential fo
Biogen Stock Hits Fresh High on Eli Lilly Buzz
10:59am, Wednesday, 03'rd May 2023
The shares of Biogen Inc (NASDAQ:BIIB) are enjoying tailwinds from positive news surrounding sector peer Eli Lilly's (LLY) Alzheimer's drug donanemab.
Eli Lilly Surges After Alzheimer's Treatment Succeeds; Biogen Also Rises
09:16am, Wednesday, 03'rd May 2023
Eli Lilly stock popped Wednesday after the company said its experimental Alzheimer's treatment significantly slowed cognitive decline. The post Eli Lilly Surges After Alzheimer's Treatment Succeeds; B
Biogen prices new ALS treatment at $14,230 per vial
12:14pm, Tuesday, 02'nd May 2023
Biogen Inc. BIIB has priced its recently approved ALS treatment Qalsody at $14,230 per vial, a spokesperson confirmed to MarketWatch on Tuesday. The drug, also known as tofersen, was granted accelerat
Alzheimer's patients may wait years to get treated with new drugs, putting them at risk of more severe disease
09:00am, Sunday, 30'th Apr 2023
Patients could face wait times ranging from 18 months to four years or more to get diagnosed and then treated for Alzheimer's disease.
The 3 Most Promising Biotech Innovations in 2023 and the Stocks to Buy
06:26am, Friday, 28'th Apr 2023
The biotech sector is up 4.76% so far in 2023. This continues the nice run that biotech stocks had in 2022.
FDA grants accelerated approval to Biogen's treatment for rare form of ALS
01:52pm, Tuesday, 25'th Apr 2023
The U.S. Food and Drug Administration said Tuesday it has granted accelerated approval to Biogen Inc.'s BIIB torferson, a treatment for a rare form of amyotrophic lateral sclerosis, or ALS. The accele
Biogen isn't concerned about competing with Eli Lilly in the Alzheimer's drug space, CEO says
01:40pm, Tuesday, 25'th Apr 2023
Biogen CEO Christopher Viehbacher said during an earnings call that Eli Lilly needs to consider maintenance doses its Alzheimer's treatment donanemab.
FDA grants accelerated approval for Biogen ALS drug that treats rare form of the disease
01:20pm, Tuesday, 25'th Apr 2023
The FDA's approval requires Biogen to further study its ALS drug tofersen to further verify its clinical benefits.
Biogen (BIIB) Beats on Q1 Earnings, Ends Some Research Programs
12:57pm, Tuesday, 25'th Apr 2023
Biogen (BIIB) beats first-quarter estimates for earnings and sales. It maintains its 2023 guidance.
Biogen Inc. (BIIB) Q1 2023 Earnings Call Transcript
12:37pm, Tuesday, 25'th Apr 2023
Biogen Inc. (BIIB) Q1 2023 Earnings Call Transcript.
Biogen Inc. (BIIB) Beats Q1 Earnings and Revenue Estimates
09:53am, Tuesday, 25'th Apr 2023
Biogen Inc. (BIIB) came out with quarterly earnings of $3.40 per share, beating the Zacks Consensus Estimate of $3.25 per share. This compares to earnings of $3.62 per share a year ago.
Alzheimer's Drugs Still Aren't Biogen's Saving Grace — But The Company Is Hopeful
08:58am, Tuesday, 25'th Apr 2023
Biogen stock fell early Tuesday as the company reiterated its outlook for declining sales despite its new Alzheimer's treatment. The post Alzheimer's Drugs Still Aren't Biogen's Saving Grace — But T
Biogen tops estimates as revenue slides 3% from a year ago
07:25am, Tuesday, 25'th Apr 2023
Biogen Inc. BIIB said Tuesday it had net income of $387.9 million, or $2.67 a share, for the first quarter, up from $303.8 million, or $2.06 a share, in the year-earlier period. Adjusted per-share ear
Better Big Biotech Buy: Biogen vs. Vertex
02:00pm, Thursday, 20'th Apr 2023
Biogen and Vertex are both waiting on big regulatory decisions for potential products. The companies each bring in billions of dollars in revenue every year.
